Currently, 4 large cardiovascular outcome trials have established the cardiovascular safety of DPP-4 inhibitors vs placebo in patients with type 2 diabetes at a high cardiovascular risk, 20-23 including the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA). Design, setting, and participants: Randomized, double-blind, active-controlled, noninferiority trial, with participant screening from November 2010 to December 2012, conducted at 607 hospital and primary care sites in 43 countries involving 6042 participants. The ongoing CARMELINA trial is examining the CV and renal safety of linagliptin in diabetic patients with high CV risk as compared to placebo. The CARMELINA trial was a long-term clinical study of the dipeptidyl peptidase 4 (DPP4) inhibitor linagliptin in patients with type 2 diabetes that confirmed the noninferiority of linagliptin plus standard of care (SoC) versus SoC for 3-point major adverse cardiovascular events. 2018 Mar 14;17(1):39. doi: 10.1186/s12933-018-0682-3. 646 n engl j med 377;7 nejm.orgAugust 17, 2017 The new england journal of medicine by the trial sponsor. with LINAgliptin (CARMELINA®):andomized, double-blind,ebo -controlled clinical trial in patients with t2es and high cardio-renal risk Julio Rosenstock1*,Vlado Perkovic 2,John H. Alexander3,Mark E. Cooper4,Nikolaus Marx5,Michael J. Pencina3, In a similar group of patients, the ongoing CAROLINA study is assessing the CV safety of linaglitin compared to … Camelina grows rapidly and, in Montana field trials, completed its lifecycle a few weeks sooner than spring wheat. Linagliptin (CARMELINA) was designed to evaluate the CV safety and kidney outcomes of linagliptin in patients with type 2 diabetes at high cardiorenal risk. Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Randomized, double-blind, placebo-controlled, multicenter noninferiority trial conducted at 605 clinic sites in 27 countries, enrolling adults with type 2 diabetes and HbA 1c 6.5-10.0%. Cardiovasc Diabetol. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. Participants in CANVAS were randomly assigned in a 1:1:1 ratio to receive cana - … CARMELINA (The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin) was designed to evaluate the cardiovascular safety and kidney outcomes of linagliptin, a highly selective DPP-4 inhibitor with minimal renal excretion, 15 in people with T2DM at high cardiovascular and renal risk. The top-line results of the CAROLINA trial indicate that linagliptin is non-inferior to glimepiride. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA(®)): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Good yields have been achieved following cereal crops on fields which would otherwise have been fallow. For a clinician who works to achieve optimal outcomes, glucose-lowering therapies form part of a multifactorial intervention package.